<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04474990</url>
  </required_header>
  <id_info>
    <org_study_id>VP-VLY-686-3303</org_study_id>
    <nct_id>NCT04474990</nct_id>
  </id_info>
  <brief_title>SINGLE-PATIENT EXPANDED ACCESS PROTOCOL FOR TRADIPITANT IN A SINGLE PATIENT WITH GASTROPARESIS</brief_title>
  <official_title>VP-VLY-686-3303: SINGLE-PATIENT EXPANDED ACCESS PROTOCOL FOR TRADIPITANT IN A SINGLE PATIENT WITH GASTROPARESIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanda Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Primary Objective: To treat a single patient with gastroparesis who has requested expanded&#xD;
      access with tradipitant&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-patient extended access treatment protocol to be conducted in the United&#xD;
      States. Investigator-Physician has determined patient satisfies expanded access inclusion&#xD;
      criteria and has requested expanded access to tradipitant.&#xD;
&#xD;
      Patient will be given open label tradipitant 85 mg to be taken twice daily at 12 hour&#xD;
      intervals for long term treatment. Patient can fill out daily web-based symptom diaries on a&#xD;
      voluntary basis and report any adverse events to Investigator-Physician.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      -To treat a single patient with gastroparesis who has requested expanded access with&#xD;
      tradipitant&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To monitor the efficacy of tradipitant in reducing individual symptoms associated with&#xD;
           gastroparesis in this single patient&#xD;
&#xD;
        -  To monitor the safety of tradipitant in a patient with gastroparesis by assessing&#xD;
           adverse events in this single patient&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Gastroparesis</condition>
  <condition>Diabetic Gastroparesis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tradipitant</intervention_name>
    <description>NK-1 Receptor antagonist</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Identified subject who requested expanded access&#xD;
&#xD;
          -  Diagnosed with gastroparesis&#xD;
&#xD;
          -  Demonstrated delayed gastric emptying&#xD;
&#xD;
          -  Presence of moderate to severe nausea&#xD;
&#xD;
          -  Patient does not qualify for or does not have access to other clinical trials with&#xD;
             tradipitant;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Another active disorder or treatment which could explain or contribute to symptoms of&#xD;
             gastroparesis&#xD;
&#xD;
          -  A positive test for drugs of abuse at the screening or evaluation visits;&#xD;
&#xD;
          -  Exposure to any investigational medication in the past 60 days other than tradipitant&#xD;
&#xD;
          -  Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric&#xD;
             stimulation device surgically implanted within the last year&#xD;
&#xD;
          -  Any other reason as determined by the Investigator which may lead to an unfavorable&#xD;
             risk-benefit ratio to treatment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Vanda Pharmaceuticals</last_name>
    <phone>2027343400</phone>
    <email>clinicaltrials@vandapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <phone>202-734-3400</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastroparesis</keyword>
  <keyword>idiopathic</keyword>
  <keyword>diabetic</keyword>
  <keyword>tradipitant</keyword>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <keyword>stomach</keyword>
  <keyword>motility</keyword>
  <keyword>functional</keyword>
  <keyword>NK-1 antagonist</keyword>
  <keyword>neurokinin 1 receptor</keyword>
  <keyword>substance p</keyword>
  <keyword>expanded access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

